← All trials
NCT04672928
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 21, 2020
- Primary completion
- May 25, 2023
- Completion date
- Nov 3, 2023
- First posted
- Dec 17, 2020
- Last posted
- Dec 28, 2020
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Innovent Biologics (Suzhou) Co. Ltd.Lead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Jilin Provincial Tumor HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.